Navigation Links
FDA Approves 1st Skin Patch to Combat Migraines
Date:1/21/2013

By Amanda Gardner
HealthDay Reporter

MONDAY, Jan. 21 (HealthDay News) -- A skin patch for the treatment of migraines, and the intense waves of nausea that often accompany these debilitating headaches, has been approved by the U.S. Food and Drug Administration.

Called Zecuity, the patch contains sumatriptan, one of the most widely prescribed medications for migraines.

According to Dr. Fawad Khan, a neurologist with Ochsner Neuroscience Institute in New Orleans, few drugs are approved for the treatment of acute, symptomatic migraine. To complicate matters, many migraine sufferers can also experience severe bouts of nausea and vomiting.

Another expert described the problem this way.

"I've had some patients where the nausea and vomiting was so bad they couldn't even swallow a pill," said Nancy Waltman, a nurse practitioner with the University of Nebraska Medical Center College of Nursing, Lincoln Division.

A nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.

Khan said the Zecuity patch is "simple, efficient and can deliver the exact amount of dosage with minimal variability."

The patch is attached to the upper arm or thigh, and when the patient pushes a button the drug is delivered through the skin. Zecuity, which is battery-operated, delivers 6.5 milligrams of sumatriptan over the course of about five hours and can relieve nausea, as well as reduce sensitivity to light and sound.

NuPathe Inc., which makes Zecuity, hopes to have the patch on the market later this year.

Research involving 800 patients ultimately led to the approval of Zecuity. One study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo. About half achieved a reduction in their headache after two hours, compared with 29 percent of those using the placebo.

And 84 percent of patients using the patch were relieved of their nausea, compared with 63 percent of those in the placebo group, according to a company news release.

The most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.

Patients with heart disease or who are using antidepressants known as selective serotonin reuptake inhibitors should also be careful when taking sumatriptans, said Waltman, who added that she thought the patches "are wonderful."

One concern, though, is cost, Waltman cautioned.

It's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.

In general, though, "the more options that are available to migraine headache patients, the better," Waltman said. "Migraine patients tend to be underdiagnosed and undertreated and inappropriately treated."

NuPathe CEO Armando Anido told Bloomberg News, "We anticipate the product will be available for sale in the fourth quarter of this year."

More information

The U.S. National Library of Medicine has more about migraines.

SOURCES: Fawad Khan, M.D., neurologist, Ochsner Neuroscience Institute, New Orleans; Nancy Waltman, Ph.D., nurse practitioner, University of Nebraska Medical Center College of Nursing, Lincoln Division; NuPathe Inc., news release, Jan. 17, 2013; Bloomberg News


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
2. FDA Approves New Type of Flu Vaccine
3. FDA Approves New Once-a-Day HIV Pill
4. FDA Approves Flu Vaccine for Coming Season
5. FDA Approves 2nd New Weight-Loss Drug
6. FDA Approves 1st Pill to Help Prevent HIV Infection
7. FDA Approves First New Weight-Loss Drug in More Than a Decade
8. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
9. FDA Approves Combo Shot for Meningitis, Hib in Kids
10. FDA Approves Generic Versions of Plavix
11. Measles vaccine given with a microneedle patch could boost immunization programs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves 1st Skin Patch to Combat Migraines
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release of ... in Cannes (France), XO Private has initiated a second print-run of its lavish luxury ... a metre across when open, weighs in at more than six kilos, retails at ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for Palliative ... in or interested in palliative care education and research. The Symposium, “Innovate. Investigate. ... County San Diego on Sept. 28 and 29, 2017, on the campus of California ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017 Report analyzes the worldwide markets for ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ... for the period 2015 through 2022. Also, a six-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/23/2017)... -- Visiomed, the French leader in medical grade ... the landscape of healthcare with their innovative use ... solutions. Recognizing the rising demand of self-monitoring alongside ... walls, Visiomed has launched BewellConnect, the most ground-breaking ... that is empowering the lives of patients. ...
Breaking Medicine Technology: